Orthocell Ltd (ASX: OCC) shares are catching the eye on Wednesday morning.
In early trade, the ASX All Ords stock is up 5% to 82 cents.
Why are Orthocell shares rising today?
The company’s shares are pushing higher today following the release of an announcement that highlights the real-world use of its Remplir device in a conflict setting.
Remplir is a collagen nerve wrap used in the repair of peripheral nerve injuries. It provides compression-free protection to the nerve, generating an ideal microenvironment to aid nerve healing.
According to the release, the ASX All Ords stock’s Remplir product has been used in 23 surgical procedures on injured soldiers in Ukraine.
The company confirmed that the procedures followed a humanitarian delivery of the device to Ukraine in April 2025, with surgeons now successfully using Remplir in both primary and secondary nerve repair operations.
The good news is that feedback from surgeons has been positive, supporting the clinical utility of the device.
Real-world validation in challenging environments
Management highlighted that this deployment demonstrates the practicality of Remplir in demanding conditions such as conflict zones.
The device is designed to connect, protect, and cap severed nerves resulting from trauma. Its portability, ease of use, and ability to be stored at room temperature make it well suited for use in military and emergency environments.
Importantly, Orthocell was able to train Ukrainian surgeons remotely via video, supported by its key opinion leader and Australian orthopedic surgeon, Dr Alex O’Beirne. The successful adoption of the product following remote instruction highlights its accessibility and ease of implementation in the field.
Defence opportunity emerging
The ASX All Ords stock believes this experience could open the door to further opportunities with defence organisations globally.
Orthocell intends to continue working with Ukrainian surgeons to monitor patient outcomes and collect clinical data where possible. This data is expected to support future discussions with defence and medical organisations around the world.
Commenting on the development, the company’s managing director, Paul Anderson, said:
In a time where there are multiple global conflicts, the application of Remplir in trauma-related nerve injuries is highly relevant. The successful remote training of surgeons and subsequent use of the device across 23 patients reinforces its unique handling, transportability, and clinical utility as a leading collagen-based nerve repair solution.
The post Which exciting ASX All Ords stock is jumping on big news? appeared first on The Motley Fool Australia.
Should you invest $1,000 in Orthocell Limited right now?
Before you buy Orthocell Limited shares, consider this:
Motley Fool investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now… and Orthocell Limited wasn’t one of them.
The online investing service he’s run for over a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.*
And right now, Scott thinks there are 5 stocks that may be better buys…
* Returns as of 20 Feb 2026
.custom-cta-button p {
margin-bottom: 0 !important;
}
More reading
- ARN Media has torn up Kyle Sandilands’ contract – so how much could it cost them?
- 2 ASX growth stocks down 40% to 60% to buy now
- Why Cochlear and ResMed shares could be strong buys
- Buying ASX shares or paying off a mortgage? Here’s what the experts are saying about RBA interest rate hikes in 2026
- CBA shares: 3 reasons to buy and 3 reasons to sell
Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has recommended Orthocell. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.